Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study

Published:2022-11-03 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Liu Kang,Qin Zhongke,Ge Yifei,Bian Ao,Xu Xueqiang,Wu Buyun,Xing Changying,Mao Huijuan

Funder

National Natural Science Foundation of China

the National Natural Science Foundation General Project

the Scientific Research Project of Jiangsu Provincial Health and Wellness Commission

the Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04437-9.pdf

Reference39 articles.

1. Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N et al (2022) Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-004421

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

3. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

4. Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract 14:247–249. https://doi.org/10.1200/JOP.18.00005

5. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426. https://doi.org/10.1056/NEJMoa1613493

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series;Cancer Immunology, Immunotherapy;2024-08-06

2. Sintilimab;Reactions Weekly;2024-05-18

3. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case–control study;BMJ Open;2024-05

4. Clinical Features Associated with Immune Checkpoint Inhibitor Nephritis: A Single-Center Clinical Case Series;2024-01-22

5. Anti-inflammatory and antipyretic analgesics and drugs used in gout;Side Effects of Drugs Annual;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3